Medivir Q2 2003

INTERIM REPORT, 1 January - 30 June 2003 · In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received upon signing and up to EUR 86 m on the achievement on specific milestones, excluding royalties. · CCS divested to the Segulah II L.P. investment fund as of 1 July 2003 for a price of SEK 210 m. This is a part of Medivir's strategy to fully focus on its R&D activities. · Successes in the preclinical research have generated several new projects within areas with large need of therapies. · Medivir's shares have been quoted on the Stockholm Exchange's Attract 40 list since 1 July. · Profit after financial items was SEK -33.3 (4.3) m. Net sales stood at SEK 138.6 (165.5) m. · CCS' net sales grew to SEK 85.6 (76.7) m. Profit after financial items was SEK 16.8 (9.6) m. FOR MORE INFORMATION, PLEASE CONTACT: Rein Piir, CFO and VP IR, tel: +46 (0)70 853 7292 FORTHCOMING FINANCIAL INFORMATION The Third-quarter Interim Report 2003 will be published on 23 October 2003. Medivir's financial reports are available at its Website, www.medivir.se from these dates, under the 'Financial Information' heading. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/07/09/20030709BIT00090/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/07/09/20030709BIT00090/wkr0002.pdf The full report